An FDA-approved treatment that halts or reverses cognitive decline in Alzheimer's disease is available before

Question

Six frontier AI models put this at 12% by 2 Nov 2036. Full reasoning from every model.

WillHappen.ai · Accepted Answer

12% — the median of 6 frontier models, resolving by 2036-11-02.

Answer

Gemini (Google): 14% — Halting or reversing neurodegeneration demands fixing synaptic damage and multi-pathway pathology that current pipeline assets cannot yet touch. FDA-cleared mAbs like lecanemab only slow decline by roughly 30%, and Phase 2/3 candidates aiming for complete arrest are virtually absent. Developing, validating, and securing approval for a novel mechanism requires an 8-to-10-year clinical horizon, leaving no room for late pipeline failures. A decisive Phase 2 signal demonstrating zero cognitive decline over 18 months in a broad cohort would rapidly double these odds.

Answer

Claude (Anthropic): 5% — No drug has reached late-stage trials showing true reversal, not just slowing, of cognitive decline. Current FDA-approved drugs (lecanemab, donanemab) only modestly slow decline, not halt or reverse it. A decade is a long window but reversal requires a fundamentally different mechanism than amyloid clearance, which hasn't shown this effect. Watch for breakthrough tau- or neuroregeneration-targeted therapies reaching Phase 3 with reversal endpoints before 2032 to change this.

Answer

GPT (OpenAI): 24% — This hinges on whether a novel disease-modifying mechanism can show durable cognitive arrest in long FDA trials. FDA must see randomized evidence of sustained no-decline or improvement, not amyloid clearance or a modest slowing effect. No Alzheimer’s drug has yet demonstrated complete arrest or reversal; pivotal programs usually need 5–8 years through Phase 3 and review. Odds rise sharply if an ongoing tau, neuroinflammation, or combination trial reports multi-year cognitive improvement by 2029.

Answer

Grok (xAI): 12% — A pipeline asset must already be in/near Phase 3 by ~2028 and show near-zero cognitive decline, not 30% slowing. Anti-amyloids (lecanemab/donanemab) slow CDR-SB 27-35%; no trial has produced arrest or reversal. Phase 3-to-FDA typically 3-5 yrs, so only assets already in mid/late development can make 2034. AD Phase 3 success historically ~1-2%. Positive 2029-31 Phase 3 with flat slopes on a new mechanism (tau/TREM2/gene tx) would move the number most.

Answer

DeepSeek (DeepSeek): 12% — Whether any Phase 3 agent can show cognitive improvement, not just slowing, and win FDA approval within nine years. Lecanemab and donanemab only slow decline ~27-35% on CDR-SB; no approved drug has shown arrest or reversal. Anti-amyloid failures dominate: aducanumab, gantenerumab, solanezumab all missed; the amyloid hypothesis has not delivered reversal in 30 years. Eisai/Biogen, Lilly, and Roche control the pipeline; a tau or anti-inflammatory breakthrough would need Phase 3 readouts by ~2032 to clear FDA by 2035.

Answer

Qwen (Alibaba): 9% — No pipeline candidate has shown anything near complete arrest; the jump from 35% slowing to zero decline is biologically enormous. Lecanemab and donanemab achieve ~27-35% slowing; no Phase 3 candidate (anti-tau, combo, gene therapy) has demonstrated complete halt as of 2026. Even a breakthrough entering Phase 3 today needs 3-4 years for trial plus 1-2 for FDA review, leaving minimal margin before 2035. A combination therapy showing >80% slowing in a 2027-2028 readout would be the most plausible path, but that still falls short of the literal 'halts' standard.

An FDA-approved treatment that halts or reverses cognitive decline in Alzheimer's disease is available before 2035.

What each one said

An FDA-approved treatment that halts or reverses cognitive decline in Alzheimer's disease is available before 2035.

A universal curative treatment for all major types of cancer is approved before 2050.

The University of Oxford conducts its space medicine program as announced between November 16 and November 20, 2026.

An autonomous surgical robot performs a complete invasive human operation without human intervention before 2032.

An FDA-approved treatment that halts or reverses cognitive decline in Alzheimer's disease becomes available before 2036.